| Size |
|
| Stage III | 8 | 16% |
| <4 cm | 17 | 34% | Stage IV | 10 | 20% |
| >4 cm | 33 | 66% |
|
|
|
| Grade |
|
| CRKL |
|
|
| Grade I | 17 | 34% | Low | 22 | 44% |
| Grade II | 18 | 36% | High | 28 | 56% |
| Grade III | 15 | 30% |
|
|
|
| LVSI |
|
| CK2 β |
|
|
| Absent | 30 | 60% | Low | 21 | 42% |
| Present | 20 | 40% | High | 29 | 58% |
| Cervical stromal invasion |
|
| Treatment |
|
|
| Absent | 22 | 44% | Surgery | 25 | 50% |
| Present | 28 | 56% | Concurrent Chemoradiation | 15 | 30% |
|
|
|
| Chemotherapy | 10 | 20% |
| Parametrial extension |
|
| Response to CRT | (N = 25) | |
| Absent | 32 | 64% | OAR | 14 | 56% |
| Present | 18 | 36% | NR | 11 | 44% |
| Serosal invasion |
|
| Follow-up duration (months) |
|
|
| Absent | 32 | 64% | Mean ± SD | 36.50 ± 15.77 | |
| Present | 18 | 36% | Median (Range) | 38.50 (12 - 60) | |
| Adnexal invasion |
|
| Recurrence | (N = 39) | |
| Absent | 32 | 64% | Absent | 33 | 84.6% |
| Present | 18 | 36% | Present | 6 | 15.4% |
| Peritoneal cytology |
|
| Progression | (N = 28) | |
| Negative | 30 | 60% | Absent | 15 | 53.6% |
| Positive | 20 | 40% | Present | 13 | 46.4% |
| Lymph node |
|
| Metastasis | (N = 40) | |
| Negative | 30 | 60% | Absent | 32 | 80% |
| Positive | 20 | 40% | Present | 8 | 20% |
| Distant metastasis |
|
| Mortality | (N = 50) | |
| Negative | 40 | 80% | Alive | 32 | 64% |
| Positive | 10 | 20% | Died | 18 | 36% |